Elite in Severe Combined Immunodeficiency (SCID)

Dr. Neena R. Kapoor

Pediatric Hematology Oncology
Childrens Hospital Los Angeles Medical Group Inc
4650 W Sunset Blvd, 
Los Angeles, CA 
46 Years of Experience
Elite in Severe Combined Immunodeficiency (SCID)
Childrens Hospital Los Angeles Medical Group Inc
4650 W Sunset Blvd, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Neena Kapoor is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Kapoor has been practicing medicine for over 46 years and is rated as an Elite provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). Her top areas of expertise are Severe Combined Immunodeficiency (SCID), Chronic Granulomatous Disease, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Endoscopy.

Her clinical research consists of co-authoring 131 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 23 articles and participated in 3 clinical trials in the study of Severe Combined Immunodeficiency (SCID).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Optima Health
  • HMO
  • POS

Locations

CHILDRENS HOSPITAL LOS ANGELES MEDICAL GROUP INC
4650 W Sunset Blvd, Los Angeles, CA 90027

Additional Areas of Focus

Dr. Kapoor has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Other
Study Phase: Not Applicable
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: February 11, 2025
Intervention Type: Biological
Study Drugs: OTQ923, HIX763, OTQ923, HIX763
Study Phase: Phase 1
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders
Expanded Access Protocol for CaspaCIDe T Cells From An HLA-Partially Matched Related Donor After Negative Selection of TCR αβ+T Cells In Pediatric Patients Affected by Hematological and Other Disorders
Enrollment Status: No_longer_available
Publish Date: October 05, 2020
Intervention Type: Biological, Drug
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
Enrollment Status: Terminated
Publish Date: May 21, 2020
Intervention Type: Genetic
A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency
A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency
Enrollment Status: Completed
Publish Date: April 16, 2020
Intervention Type: Biological
Study Phase: Phase 3
View 11 Less Clinical Trials
Similar Doctors
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Donald B. Kohn
Pediatric Hematology Oncology
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Donald B. Kohn
Pediatric Hematology Oncology
4650 W Sunset Blvd, Ms# 62, 
Los Angeles, CA 
 (0.1 miles away)
323-669-4559
Languages Spoken:
English
See accepted insurances

Donald Kohn is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Kohn is rated as an Elite provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Severe Combined Immunodeficiency (SCID), Adenosine Deaminase Deficiency, X-Linked Severe Combined Immunodeficiency, Hemoglobinopathy, and Bone Marrow Transplant.

Elite in Severe Combined Immunodeficiency (SCID)
Dr. Theodore B. Moore
Pediatric Hematology Oncology
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Theodore B. Moore
Pediatric Hematology Oncology
10833 Le Conte Ave, 12-441 Mdcc, 
Los Angeles, CA 
 (9.0 miles away)
310-825-6708
Languages Spoken:
English
See accepted insurances

Theodore Moore is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Moore is rated as a Distinguished provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Severe Combined Immunodeficiency (SCID), Sickle Cell Disease, Adenosine Deaminase Deficiency, Congenital Hemolytic Anemia, and Bone Marrow Transplant.

Distinguished in Severe Combined Immunodeficiency (SCID)
Dr. David K. Buchbinder
Pediatric Hematology Oncology
Distinguished in Severe Combined Immunodeficiency (SCID)
Dr. David K. Buchbinder
Pediatric Hematology Oncology

Childrens Hospital Of Orange County

1201 W La Veta Ave, 
Orange, CA 
 (32.7 miles away)
888-770-2462
Languages Spoken:
English
See accepted insurances

David Buchbinder is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Buchbinder is rated as a Distinguished provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency (SCID), X-Linked Severe Combined Immunodeficiency, Bone Marrow Transplant, and Bone Graft.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kapoor's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile